Author, as appears in the article.: Masana, L; Zambon, A; Schmitt, CP; Taylan, C; Driemeyer, J; Cohen, H; Buonuomo, PS; Alashwal, A; Al-Dubayee, M; Diaz-Diaz, JL; Maatouk, F; Hervás, SM; Mangal, B; Löwe, S; Cunningham, T
Department: Medicina i Cirurgia
URV's Author/s: Masana Marín, Luis
Thematic Areas: Cardiology and cardiovascular medicine Internal medicine Peripheral vascular disease
licence for use: https://creativecommons.org/licenses/by/3.0/es/
Author's mail: luis.masana@urv.cat
Author identifier: 0000-0002-0789-4954
Record's date: 2024-02-17
Papper version: info:eu-repo/semantics/publishedVersion
Link to the original source: https://www.sciencedirect.com/science/article/pii/S2667089523000214?via%3Dihub
Papper original source: Atherosclerosis Plus. 54 S9-S9
APA: Masana, L; Zambon, A; Schmitt, CP; Taylan, C; Driemeyer, J; Cohen, H; Buonuomo, PS; Alashwal, A; Al-Dubayee, M; Diaz-Diaz, JL; Maatouk, F; Hervás, SM; (2023). Lomitapide for the treatment of paediatric homozygous familial hypercholesterolaemia patients - Results from the efficacy phase of the APH-19 study. Atherosclerosis Plus, 54(), S9-S9. DOI: 10.1016/j.athplu.2023.07.008
Licence document URL: https://repositori.urv.cat/ca/proteccio-de-dades/
Article's DOI: 10.1016/j.athplu.2023.07.008
Entity: Universitat Rovira i Virgili
Journal publication year: 2023
Publication Type: Journal Publications
Repositori URV